Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro.
TLDR
It is found that a reduction of HIF-1α expression in BCPAP cells was observed after treatment with IDF-11774 in a dose-dependent manner, suggesting that promoting the degradation of Hif-1 α could be a strategy to manage progression and that HIF -1α inhibitors are potent drugs for thyroid cancer treatment.Abstract:
Hypoxia-inducible factor (HIF)-1α plays an important role in cancer progression. In various cancers, including thyroid cancer, overexpression of HIF-1α is related to poor prognosis or treatment response. However, few studies have investigated the role of HIF-1α inhibition in thyroid cancer progression. We evaluated the utility of the HIF-1α inhibitor IDF-11774 in vitro utilizing two thyroid cancer cell lines, K1 and BCPAP. Both cell lines were tested to elucidate the effects of IDF-11774 on cell proliferation and migration using soft agar and invasion assays. Here, we found that a reduction of HIF-1α expression in BCPAP cells was observed after treatment with IDF-11774 in a dose-dependent manner. Moreover, cell proliferation, migration, and anchorage-independent growth were effectively inhibited by IDF-11774 in BCPAP cells but not in K1 cells. Additionally, invasion of BCPAP but not K1 cells was controlled with IDF-11774 in a dose-dependent manner. Our findings suggest that promoting the degradation of HIF-1α could be a strategy to manage progression and that HIF-1α inhibitors are potent drugs for thyroid cancer treatment.read more
Citations
More filters
Journal ArticleDOI
Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy.
TL;DR: In this article, the six parameters governing the radiotherapy response, called the six Rs of radiation biology (for Radiosensitivity, Repair, Repopulation, Redistribution, Reoxygenation, and Reactivation of anti-tumor immune response), are discussed.
Journal ArticleDOI
Small molecule inhibitors targeting the cancers
TL;DR: To better promote the development of small molecule inhibitor targeting cancers, a comprehensively reviewed small molecule inhibitors involved in all the approved agents and pivotal drug candidates in clinical trials arranged by the signaling pathways and the classification ofsmall molecule inhibitors.
Journal ArticleDOI
Poorly Differentiated Thyroid Carcinoma: Single Centre Experience and Review of the Literature.
Maria Irene Bellini,Marco Biffoni,Renato Patrone,Maria Carola Borcea,Maria Ludovica Costanzo,Tiziana Garritano,Rossella Melcarne,Rosa Menditto,Alessio Metere,Chiara Scorziello,Marco Summa,Luca Ventrone,Vito D'Andrea,Laura Giacomelli +13 more
TL;DR: In this article, the authors describe the epidemiology, diagnosis, and management of PDTC and report their single centre experience to add to the limited evidence existing in the literature, which has important prognostic and therapeutic significance.
Journal ArticleDOI
HIF1α: A Novel Biomarker with Potential Prognostic and Immunotherapy in Pan-cancer
TL;DR: The results found that there were differences in the mRNA expression levels of Hif1α in human pan-cancer and its corresponding normal tissues and the HIF1α methylation level in most tumors is significantly reduced.
Journal ArticleDOI
Targeted inhibition of the GRK2/HIF-1α pathway is an effective strategy to alleviate synovial hypoxia and inflammation.
TL;DR: In this paper , the role of HIF-1α and GRK2 in RA pathophysiology, focusing on their proinflammatory roles in immune cells and fibroblast-like synoviocytes (FLS).
References
More filters
Journal ArticleDOI
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R. Haugen,Erik K. Alexander,Keith C. Bible,Gerard M. Doherty,Susan J. Mandel,Yuri E. Nikiforov,Furio Pacini,Gregory W. Randolph,Anna M. Sawka,Martin Schlumberger,Kathryn G. Schuff,Steven I. Sherman,Julie Ann Sosa,David L. Steward,R. Michael Tuttle,Leonard Wartofsky +15 more
TL;DR: Evidence-based recommendations are developed to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer and represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Journal ArticleDOI
Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers,Douglas Hanahan +1 more
TL;DR: Emerging data support a proposition that two modes of unconventional resistance underlieAngiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
Journal ArticleDOI
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
TL;DR: A more thorough understanding of the unique roles performed by HIF1α and HIF2α in human neoplasia is warranted.
Journal ArticleDOI
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy
Cosimo Durante,Nadia Haddy,Eric Baudin,Sophie Leboulleux,D. Hartl,Jean-Paul Travagli,Bernard Caillou,Marcel Ricard,Jean Lumbroso,F. de Vathaire,Martin Schlumberger +10 more
TL;DR: Thyroxine treatment is highly effective in younger patients with (131)I uptake and with small metastases and should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered.
Journal ArticleDOI
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
TL;DR: Among patients in the United States diagnosed with thyroid cancer from 1974-2013, the overall incidence of thyroid cancer increased 3% annually, with increases in the incidence rate and thyroid cancer mortality rate for advanced-stage papillary thyroid cancer.
Related Papers (5)
Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer.
Haiyan Wei,F Li,P Fu,Xiyong Liu +3 more